Jianlin Zhou

Jianlin Zhou


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
QHQiongjie Hu
Qiongjie Hu
SWShaofang Wang
Shaofang Wang
LMLi Ma
Li Ma
ZSZiyan Sun
Ziyan Sun
ZLZilin Liu
Zilin Liu
JZJianlin Zhou
Jianlin Zhou
Immune checkpoint inhibitors (ICIs) therapy have revolutionized advanced lung cancer care. Interestingly, the host responses for patients received ICIs therapy are distinguishing from those with cytotoxic drugs, showing potential initial transient worsening of disease burden, pseudoprogression and delayed time to treatment response. Thus, a new imaging criterion to evaluate the response for immunotherapy should be developed. ICIs treatment is associated with unique adverse events, including potential life‐threatening immune checkpoint inhibitor‐related pneumonitis (ICI‐pneumonitis) if treated patients are not managed promptly. Currently, the diagnosis and clinical management of ICI‐pneumonitis remain challenging. As the clinical manifestation is often nonspecific, computed tomography (CT) scan and X‐ray films play important roles in diagnosis and triage. This article reviews the complications of immunotherapy in lung cancer and illustrates various radiologic patterns of ICI‐pneumonitis. Additionally, it is tried to differentiate ICI‐pneumonitis from other pulmonary pathologies common to lung cancer such as radiation pneumonitis, bacterial pneumonia and coronavirus disease of 2019 (COVID‐19) infection in recent months. Maybe it is challenging to distinguish radiologically but clinical presentation may help.

9 June 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
ZLZilin Liu
Zilin Liu
XWXuezhong Wang
Xuezhong Wang
JLJianping Li
Jianping Li
XYXiaoming Yang
Xiaoming Yang
JHJun Huang
Jun Huang
YHYong Hu
Yong Hu

21 September 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
ZLZilin Liu
Zilin Liu
JHJun Huang
Jun Huang
XWXuezhong Wang
Xuezhong Wang
SDShuang Deng
Shuang Deng
JZJianlin Zhou
Jianlin Zhou
YHYong Hu
Yong Hu

22 December 2020 in PPAR Research
Verified
Journal Article
Open access
PDF file
XDXianjin Du
Xianjin Du
MWMiao Wu
Miao Wu
DTDan Tian
Dan Tian
JZJianlin Zhou
Jianlin Zhou
LWLu Wang
Lu Wang
LZLiying Zhan
Liying Zhan
The severity of sepsis may be associated with excessive inflammation, thus leading to acute liver injury. MicroRNA-21 is highly expressed in the liver of a variety of inflammation-related diseases, and PPARα is also proved to participate in regulating inflammation. In the present study, the LPS-induced sepsis model was established. We found that microRNA-21 expression was upregulated in the liver of sepsis mice, and microRNA-21 inhibition significantly reduced the liver injury. The expression of liver injury markers, inflammation cytokines, and PPARα in the septic mice was higher than in antagomir-21 treated septic mice. In addition, we also found that PPARα is the target gene of microRNA-21; PPARα antagonist GW6471 could reverse the effect of antagomir-21. In conclusion, our study illustrated that microRNA-21 exacerbate acute liver injury in sepsis mice by inhibiting PPARα expression.

1 January 2016 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
JZJianlin Zhou
Jianlin Zhou
HFHong-Song Fang
Hong-Song Fang
HPHao Peng
Hao Peng
SDShuang Deng
Shuang Deng
SCShen Chen
Shen Chen
FLFeng Liu
Feng Liu
Jian-lin Z, et al. Yonsei Med J. 2016 May;57(3):735-740. https://doi.org/10.3349/ymj.2016.57.3.735

31 August 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YZYubiao Zhang
Yubiao Zhang
MCMao Chen
Mao Chen
WCWenxiang Cai
Wenxiang Cai
YZYundong Zhou
Yundong Zhou
JKJunjie Kuang
Junjie Kuang
WJWenyi Jin
Wenyi Jin
Osteoarthritis (OA) is driven in part by chondrocyte senescence, mitochondrial dysfunction and chronic inflammation, yet disease-modifying therapies that directly target these ageing mechanisms are lacking. Here, we identify the grape-seed-derived polyphenol procyanidin C1 (PCC1) as a senotherapeutic candidate that preserves chondrocyte mitochondrial homoeostasis and attenuates senescence via activation of the Nrf2/HO-1 axis. In tert-butyl hydroperoxide-induced senescent chondrocytes, PCC1 reduced senescence-associated β-galactosidase activity, dampened secretion of senescence-associated secretory phenotype factors, restored mitochondrial membrane potential and dynamics, limited extracellular matrix degradation and suppressed NF-κB activation. Network pharmacology and transcriptomic analyses converged on Nrf2 as a potential molecular target of PCC1, which we validated using cellular thermal shift and drug affinity responsive target stability assays. Genetic silencing of Nrf2 abrogated PCC1-mediated protection in vitro, confirming that Nrf2 is required for the anti-senescent and mitochondrial effects of PCC1. In a surgically induced anterior cruciate ligament transection model of OA, PCC1 administration reduced cartilage erosion, preserved matrix organisation and subchondral bone structure, and mitigated synovial inflammation in Nrf2-sufficient mice, whereas Nrf2 deficiency abolished these benefits. Together, these findings establish a mechanistic link between PCC1, Nrf2/HO-1 activation and chondrocyte mitochondrial homoeostasis in osteoarthritis, and support Nrf2-directed senotherapies as a regenerative strategy to slow OA progression.